OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4929562_AE29562_0